Skip to Content
Black Friday offer ends in

Biomarkers in Critical Care,An Issue of Critical Care Clinics, 1st Edition

Author :
Mitchell Levy
Date of Publication: 11/2019
This issue of Critical Care Clinics, guest edited by Dr. Mitchell M. Levy, focuses on Biomarkers in Critical Care. This is one of four issues each year selected by the series consulting editor, Dr. John Kellum. Articles in this issue include, but are ...view more
This issue of Critical Care Clinics, guest edited by Dr. Mitchell M. Levy, focuses on Biomarkers in Critical Care. This is one of four issues each year selected by the series consulting editor, Dr. John Kellum. Articles in this issue include, but are not limited to: The History of Biomarkers; Biomarkers for Identifying Infection; Procalcitonin: Where Are We Now?; Soluble TREM-1: Diagnosis or Prognosis?; Lubricin as a Biomarker in Sepsis; Check Point Inhibitors and Their Role in Immunosuppression in Sepsis; Metabolomics and the Microbiome as Biomarkers in Sepsis; Lactate: Where Are We Now?; Predicting Renal Dysfunction; Biomarkers in the Evolution of ARDS; Biomarkers and RV Dysfunction; Biomarkers and Precision Medicine: State of the Art; The Use of Biomarkers for Population Homogeneity in Clinical Trials; and The Future of Biomarkers.
Add to Cart
This issue of Critical Care Clinics, guest edited by Dr. Mitchell M. Levy, focuses on Biomarkers in Critical Care. This is one of four issues each year selected by the series consulting editor, Dr. John Kellum. Articles in this issue include, but are not limited to: The History of Biomarkers; Biomarkers for Identifying Infection; Procalcitonin: Where Are We Now?; Soluble TREM-1: Diagnosis or Prognosis?; Lubricin as a Biomarker in Sepsis; Check Point Inhibitors and Their Role in Immunosuppression in Sepsis; Metabolomics and the Microbiome as Biomarkers in Sepsis; Lactate: Where Are We Now?; Predicting Renal Dysfunction; Biomarkers in the Evolution of ARDS; Biomarkers and RV Dysfunction; Biomarkers and Precision Medicine: State of the Art; The Use of Biomarkers for Population Homogeneity in Clinical Trials; and The Future of Biomarkers.

Author Information
Edited by Mitchell Levy, MD, MCCM, FCCP, Systemwide Director, Critical Care Medicine Lifespan Health and Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Warren Alpert Medical School at Brown University, Providence, Rhode Island